How Fedasz was paid
$352,060 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Total |
|---|---|---|---|
| Ralph SchiessFormer Chief Executive Officer and Former Chief Science Officer | $163,937 | — | $163,937 |
| Karina FedaszInterim Chief Financial Officer and Former Interim Chief Executive Officer | $307,060 | $45,000 | $352,060 |
What changed and why
- $352K$352,060 was Karina Fedasz’s total 2025 compensation, up from $197,125 in 2024.
- $45,000$45,000 bonus was awarded to Fedasz for serving as interim CEO during 2025.
- $164K$163,937 was Ralph Schiess’s 2025 compensation before his executive roles ended.
- $21,700March 18, 2026 marked David White’s appointment as CEO at a monthly base salary of $21,700.
- No named executive officer held outstanding equity incentive awards at December 31, 2025.
Other Onconetix proxy statements
- 2025 proxy statement
Ralph Schiess paid $305,176 (+189% on the year).
Filed Nov 10, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.